Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

Keyphrases

• Polyneuropathy 100%
• Long-term Safety 100%
• Long-term Efficacy 100%
• Open-label Extension 100%
• Transthyretin Amyloidosis 100%
• Patisiran 100%
• Apollo 66%
• Placebo Groups 28%
• Neuropathy Disability Score 14%
• Efficacy Assessment 9%
• Serious Adverse Events 9%
• Extension Trial 9%
• Hospital Center 4%
• Placebo 4%
• Long-term Treatment 4%
• Treatment-related Adverse Events 4%
• Adverse Events 4%
• Quality of Life 4%
• Group Studies 4%
• Disability 4%
• Clinical Centers 4%
• Motor Function 4%
• Nutritional Status 4%
• Disease Burden 4%
• RNA Interference 4%
• Safety Profile 4%
• Intravenous Infusion 4%
• Progressive Disease 4%
• Safety Assessment 4%
• Safety Analysis 4%
• Cardiac Stress 4%
• Group 13 4%
• Mean Group 4%
• Infusion Reaction 4%
• Acceptable Safety 4%
• Interim Analysis 4%
• Transthyretin 4%
• Overall Assessment 4%
• Autonomic Symptoms 4%
• Ambulation Status 4%
• Transthyretin Gene 4%

Medicine and Dentistry

• Amyloidosis 100%
• Polyneuropathy 100%
• Transthyretin 100%
• Patisiran 100%
• Placebo 33%
• Adverse Event 19%
• Neuropathy 14%
• Efficacy Assessment 9%
• Symptom 4%
• Quality of Life 4%
• Motor Performance 4%
• Nutritional Status 4%
• Intravenous Drug Administration 4%
• Disease Burden 4%
• Progressive Disease 4%
• Mobilization 4%
• Infusion Related Reaction 4%
• Interim Analysis 4%
• RNAi Therapeutics 4%
• Heart Stress 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Polyneuropathy 100%
• Amyloidosis 100%
• Transthyretin 100%
• Patisiran 100%
• Placebo 33%
• Adverse Event 19%
• Neuropathy 14%
• Disease 9%
• Efficacy Assessment 9%
• Symptom 4%
• Infusion Related Reaction 4%
• Heart Stress 4%